Welcome to our dedicated page for Pacira Biosciences news (Ticker: PCRX), a resource for investors and traders seeking the latest updates and insights on Pacira Biosciences stock.
Overview
Pacira BioSciences Inc (NASDAQ: PCRX) is a specialty pharmaceutical company committed to revolutionizing pain management by offering innovative non-opioid therapies and regenerative health solutions. With a core focus on providing safe and effective alternatives for pain control, the company leverages its proprietary drug delivery platforms to address acute pain in surgical and chronic conditions. Its approach combines advanced pharmaceutical formulations with novel medical devices, ensuring that clinicians have access to effective treatment options that reduce reliance on opioids.
Core Technologies and Products
At the heart of Pacira's innovation is its unique product delivery technology, which encapsulates active compounds without altering their molecular structures. This platform enables controlled, extended release of medications, ensuring long-lasting efficacy. The company has successfully commercialized several non-opioid treatments:
- EXPAREL: A long-acting local anesthetic designed to provide postsurgical pain control through sustained drug release, thereby reducing the need for opioids.
- ZILRETTA: An extended-release intra-articular injection indicated for the management of osteoarthritis knee pain, offering patients prolonged relief.
- iovera®: A handheld, drug-free device that applies controlled doses of cold therapy to targeted nerves, providing immediate and lasting pain relief.
In addition to these commercial products, Pacira is advancing its pipeline with a novel gene therapy candidate, PCRX-201. This locally administered therapy aims to treat osteoarthritis by regulating inflammatory pathways, thus addressing the root causes of pain and disability.
Market Position and Business Model
Pacira BioSciences operates at the intersection of innovative drug delivery and non-opioid pain management solutions. Its business model emphasizes:
- Commercialization of Proven Therapies: The company has established a presence in markets requiring effective postsurgical and chronic pain management solutions, evidenced by the wide adoption of its therapies in diverse clinical settings.
- Advanced R&D and Pipeline Development: By investing in robust research and development programs, along with strategic partnerships, Pacira continues to expand its portfolio and maintain competitive differentiation in the specialty pharmaceutical sector.
- Regulatory and Reimbursement Strategies: With products that have secured critical reimbursement designations, Pacira enhances market access for its non-opioid therapies across different healthcare settings. This strategic emphasis supports clinician adoption and broader patient access.
Clinical and Commercial Significance
The company's focus on non-opioid pain management comes at a time when reducing opioid dependency is an urgent priority in healthcare. By developing treatments that not only manage pain effectively but also minimize opioid consumption, Pacira is addressing a key public health challenge. Its clinically validated products have been incorporated into pain management protocols in hospitals and outpatient settings alike, offering enduring benefits for patients and healthcare providers.
Innovative Edge and Future Pipeline
Pacira’s utilization of advanced drug delivery systems, such as multivesicular liposomes and precise cryoneurolysis, underscores its commitment to innovation. These technologies not only improve therapeutic outcomes but also facilitate streamlined billing and regulatory approval processes through established coding systems. With an evolving pipeline that includes gene therapy approaches, the company is poised to expand its reach into additional therapeutic areas, addressing unmet needs in the treatment of chronic and musculoskeletal pain.
Competitive Landscape and Differentiators
In a competitive market, Pacira differentiates itself through its deep expertise in non-opioid pain management and its commitment to technological advancements. The integration of robust clinical data, strategic reimbursement initiatives, and a focus on delivering sustained therapeutic benefits positions the company as a trusted innovator among healthcare practitioners. Unlike traditional pain management solutions that rely heavily on opioids, Pacira’s products are designed to provide effective relief with reduced risk of dependency, offering a clinically superior alternative in the evolving landscape of pain management.
Conclusion
With a comprehensive portfolio that spans commercial-stage products and a promising pipeline, Pacira BioSciences Inc stands as a key player in the specialty pharmaceutical industry. Its ongoing commitment to developing non-opioid pain therapies, underpinned by advanced drug delivery technologies and rigorous clinical validation, ensures that it remains an authoritative source of innovation and expertise in pain management and regenerative health.
Pacira BioSciences, Inc. (NASDAQ:PCRX) will report its fourth quarter and year-end financial results for December 31, 2021, on February 24, 2022, prior to market opening. A live conference call and webcast will follow at 8:30 a.m. ET, allowing participants to engage directly. Interested parties can access the event through the company’s investor webpage. Pacira focuses on non-opioid pain management solutions and has three commercial products: EXPAREL, ZILRETTA, and iovera, aimed at reducing opioid dependency in pain treatment.
Pacira BioSciences (Nasdaq: PCRX) announced preliminary unaudited net product sales for EXPAREL and iovera° for January 2022. EXPAREL's net sales reached $36.3 million, a 4% increase from January 2021, with average daily sales at 104% of the previous year. Iovera° sales remained steady at $1.1 million. CEO Dave Stack reported growth trends for EXPAREL and the ongoing launch of the next-generation iovera° device. However, the company did not provide 2022 financial guidance due to ongoing uncertainty surrounding COVID-19's impact on elective surgeries.
Pacira BioSciences (Nasdaq: PCRX) reported record net product sales of $506.5 million for 2021, marking a 25.8% increase from 2020. Fourth quarter sales of EXPAREL reached $139.9 million, driven by strong growth, although affected by COVID-19-related restrictions in December. The company also recognized sales of ZILRETTA and iovera°, contributing to total revenue of $540.7 million to $541.7 million for the year. Despite challenges posed by the pandemic, Pacira remains optimistic about future growth in non-opioid pain management solutions.
Pacira BioSciences, Inc. (NASDAQ: PCRX) will present at the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 3:00 PM ET. Interested parties can access the live audio via the company's website, with a replay available for two weeks post-event. Pacira is dedicated to providing non-opioid pain management solutions and has three commercial-stage products: EXPAREL®, ZILRETTA®, and ioveraº®. Their mission focuses on reducing reliance on opioids and developing innovative treatments for chronic pain and related conditions.
Pacira BioSciences (Nasdaq: PCRX) has successfully closed a $375 million Senior Secured Term Loan B Facility, enhancing its operational and financial flexibility. The proceeds will be utilized for general corporate purposes, including replenishing funds from the recent acquisition of Flexion Therapeutics and repaying existing convertible senior notes. CFO Charles Reinhart emphasizes confidence in the company's forecasted earnings and operating cash flow, supporting their five-year growth plan aimed at revenue and earnings expansion.
Pacira BioSciences (Nasdaq: PCRX) announced preliminary net product sales for November 2021, reporting EXPAREL sales of $46.5 million, a 22% increase from $38.1 million in November 2020. Average daily sales for EXPAREL reached 122% of the previous year. Iovera° reported $1.5 million in sales, up from $0.8 million. The company expects ZILRETTA sales to improve in 2022 following the acquisition of Flexion Therapeutics. Despite these growth trends, uncertainties related to the COVID-19 pandemic and the elective surgery market persist, leading to no financial guidance for 2021.
Pacira BioSciences, Inc. (NASDAQ: PCRX) will participate in an analyst-led fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference on November 30, 2021, at 9:30 AM ET. Investors can access the live audio on the company's website under the 'Events' section. A replay will be available for two weeks after the event. Pacira focuses on providing non-opioid treatments, including EXPAREL®, ZILRETTA®, and ioveraº®, aimed at managing pain and reducing opioid reliance.
Pacira BioSciences has completed its acquisition of Flexion Therapeutics, enhancing its offerings in non-opioid pain management. This strategic move incorporates ZILRETTA, a patented treatment for osteoarthritis knee pain, into Pacira's portfolio, allowing earlier intervention for patients. The acquisition is expected to diversify revenue streams and enhance cash flows substantially. CEO David Stack emphasized the significance of this deal in evolving pain management and reducing opioid reliance.
Pacira BioSciences, Inc. (NASDAQ: PCRX) will participate in an analyst-led fireside chat at the Jefferies London Healthcare Conference on November 16, 2021, at 11:20 AM GMT. Live audio of the event can be accessed through the company’s website, with a replay available for two weeks after. Pacira is a leader in non-opioid pain management solutions, highlighted by its long-acting local analgesic, EXPAREL, launched in April 2012. The company aims to reduce opioid reliance through innovative therapies and technologies.
Pacira BioSciences (Nasdaq: PCRX) reported preliminary unaudited net product sales for October 2021, noting that EXPAREL achieved sales of $42.5 million, a 4.4% increase from $40.7 million in October 2020. Average daily sales for EXPAREL rose to 109% compared to last year. Sales of iovera° were $1.2 million, up from $1.0 million in the same period. CEO Dave Stack expressed confidence in strong growth ahead, citing improved market conditions for elective surgeries. The company also plans to integrate ZILRETTA post-acquisition of Flexion Therapeutics, aiming for annual growth in the high teens and over 50% operating margins.